Diseases / Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
DiseasePulmonary arterial hypertension is a progressive pulmonary vascular disease characterized by elevated pulmonary arterial pressure and vascular remodeling, which can lead to right ventricular failure.
- Trials
- 690
- Recruiting
- 76
- Completed
- 339
- With results
- 171
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 2 | 1 | — | 1 | — | — | 5 |
| Phase 1 | 4 | 3 | — | — | 52 | 6 | 4 | 1 | — | — | 70 |
| Phase 1/2 | 3 | 1 | — | — | 6 | 1 | 1 | 2 | — | — | 14 |
| Phase 2 | 12 | 7 | — | 3 | 58 | 25 | 6 | 5 | — | — | 116 |
| Phase 2/3 | 1 | — | — | 2 | 4 | 1 | — | 1 | — | — | 9 |
| Phase 3 | 10 | 2 | 1 | 4 | 56 | 21 | 8 | 2 | — | — | 104 |
| Phase 4 | 4 | 3 | — | 2 | 28 | 14 | 6 | 6 | — | — | 63 |
| Not applicable | 13 | 16 | — | 5 | 47 | 4 | 7 | 29 | — | — | 121 |
| Unknown | 28 | 12 | 3 | 5 | 86 | 10 | 5 | 33 | 1 | 5 | 188 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Pulmonary Arterial Hypertension | 5 | 70 | 14 | 116 | 9 | 104 | 63 | 121 | 188 | 690 |
| Hypertension, Pulmonary | 1 | 9 | — | 38 | 2 | 31 | 14 | 32 | 58 | 185 |
| Familial Primary Pulmonary Hypertension | — | 2 | 1 | 9 | — | 5 | 1 | 5 | 9 | 32 |
| Heart Failure | — | 1 | 1 | 2 | — | — | 3 | 3 | 8 | 18 |
| Lung Diseases, Interstitial | — | — | — | 5 | — | 1 | 2 | 3 | 7 | 18 |
| Lung Diseases | — | 3 | — | 4 | 1 | 3 | — | 1 | 4 | 16 |
| Cardiovascular Diseases | — | 2 | — | 3 | 1 | 5 | 1 | 3 | — | 15 |
| Heart Defects, Congenital | — | — | — | 1 | — | 1 | — | 8 | 5 | 15 |
| Hypertension | — | — | — | 3 | — | 7 | — | — | 5 | 15 |
| Connective Tissue Diseases | — | 1 | — | 4 | — | 5 | 1 | 1 | 1 | 13 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Actelion | 59 | 30 |
| 2 | United Therapeutics | 44 | 14 |
| 3 | Bayer | 19 | 3 |
| 4 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 13 | 3 |
| 5 | Bial - Portela C S.A. | 12 | 0 |
| 6 | Merck Sharp & Dohme LLC | 12 | 3 |
| 7 | Novartis Pharmaceuticals | 12 | 6 |
| 8 | Assistance Publique - Hôpitaux de Paris | 10 | 2 |
| 9 | Pfizer | 10 | 4 |
| 10 | University of Sao Paulo General Hospital | 10 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | treprostinil | 43 |
| 2 | Sildenafil Citrate | 34 |
| 3 | Bosentan | 29 |
| 4 | ambrisentan | 24 |
| 5 | Iloprost | 21 |
| 6 | macitentan | 21 |
| 7 | ACE-011 | 17 |
| 8 | Tadalafil | 17 |
| 9 | selexipag | 15 |
| 10 | riociguat | 12 |
Evidence
- Results reported
- 50.4%171 of 339 completed
- Published
- 13%44 of 339 completed
- Primary endpoint met
- 46.2%48 of 104 analyses
- Median months to report
- 13
Documents disclosed
Trial profile
- Median enrollment
- 44
- Median duration
- 31months
- Countries
- 67
- Study sites
- 5609
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 10
- Phase 1
- 25
- Phase 1/2
- 24
- Phase 2
- 31
- Phase 2/3
- 90
- Phase 3
- 156
- Phase 4
- 30
- Not applicable
- 40
- Unknown
- 100
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 112 |
| 2 | Dallas | United States | 97 |
| 3 | Pittsburgh | United States | 92 |
| 4 | New York | United States | 90 |
| 5 | Houston | United States | 89 |
| 6 | Los Angeles | United States | 88 |
| 7 | Cincinnati | United States | 78 |
| 8 | Aurora | United States | 72 |
| 9 | London | United Kingdom | 72 |
| 10 | Rochester | United States | 70 |
Terminations
- Terminated
- 83
- Withdrawn
- 37
- Stopped for recruitment
- 4.3%30 of 690 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06643143 Withdrawn | Withdrawn | Study has undergone sponsorship and design changes. | 2027-06-30 |
| NCT04254289 Withdrawn | Withdrawn | Lack of enrollment | 2025-12-31 |
| NCT04954742 Terminated | Terminated | Strategic re-prioritization by the IMP supplier. Decision not safety-related | 2025-08-13 |
| NCT04811092 Terminated | Terminated | Study was stopped early due to loss of clinical equipoise based on robust evidence of clinical benefit of sotatercept demonstrated in previous studies. | 2025-04-03 |
| NCT06493461 Terminated | Terminated | Sponsor's Decision | 2025-03-31 |
| NCT05975905 Terminated | Terminated | The study was voluntarily terminated early, following a safety review and observation of pericardial effusions. | 2025-03-11 |
| NCT05060315 Terminated | Terminated | Sponsor Decision | 2024-12-31 |
| NCT03782818 Terminated | Terminated | The recruitment was stopped on October 31st 2024 due to limited recruitment within the last year, as well as the end of funding (Spring 2025). | 2024-10-31 |
| NCT02525926 Terminated | Terminated | Refusal of CPP to extend the period of inclusion | 2024-10-17 |
| NCT05036135 Terminated | Terminated | The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study. | 2024-08-09 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Pulmonary Arterial Hypertension trials on ClinicalTrials.gov →